



Drug Utilization Review Board Meeting Minutes

May 11, 2021

Webex virtual webinar

DUR Board Members in attendance: Kevin Borchert, RP; Tim Bourke, RP; Charlie Moore, RP; MD; David Randolph, RP; Anthony Ross, MD; Phil Vuchetich, RP; Bruce Houghton, MD; Robert Wergin, MD

DUR Board Member not in attendance: Susan Howard, MD,

DHHS attendees: Ken Saunders, RP; Leah Spencer, R.N; Dianne Garside, RP; Spencer Moore, RP

Contracted attendees: Nikia Bennette-Carter, RP, Magellan Rx Management, Jenni Pandak, Magellan RX Management; Jamie Benson, RP, Nebraska Total Care; Maria Martin, RP, Nebraska Total Care; Shannon Nelson, RP, Healthy Blue Nebraska; Bernadette Ueda, RP, United Health Care.

Numerous Public visitors were in attendance per Webex webinar.

I. Call to Order:

The meeting was called to order by Ken Saunders on May 11, 2021 at 6:35 pm CDT. Members and attendees were welcomed. The Open-Meetings Act was reviewed and made known as available on the NE Medicaid pharmacy website.

II. Conflict of Interest

No conflicts of interest were declared.

III. Agenda approval

The May 11, 2021 meeting agenda was accepted as presented. Motion by Vuchetich and second by Wergin. Unanimous vote in the affirmative.

IV. Meeting Minutes; January 12, 2021 and March 9, 2021

Kevin Borchert reviewed and presented various grammatical, spelling, or other edits for the previous two DUR Board meetings. Motion by Borchert and second by Houghton to approve the

edited minutes. The minutes for the two meetings were voted upon and passed as edited by the DUR Board members; with Wergin abstaining.

V. Update on Recommendations (January 2021 / March 2021) meetings - DUR Board Policy

A discussion concerning the definition of a quorum, voting on items with and without a quorum and updating the DUR Board Policy was spearheaded by Vuchetich and Borchert. Motion by Borchert with second by Houghton to accept the language proposed by Vuchetich. Motion based upon that discussion, was voted upon and passed by DUR Board members. Ken Saunders finalized the editing of the DUR Board Policy Statement with the DUR Board members. He will distribute the final document via email to the DUR Board Members for their final review. This will be placed on the DUR Board website for Public view.

VI. Retrospective DUR

Spencer Moore brought up the MME data discussion of how Nebraska ranks with the neighboring states that was requested by Vuchetich in the March 2021 meeting. The MCO's are providing the state the data specific to Nebraska and this will be reported out during the July 2021 meeting. CMS leaves the MME limits up to the state and Nebraska uses the 90 MME as its benchmark. Other states have different values. Moore called for comments and Houghton made the point of with every 6 month PA's for patients with > 90 MME's, it would be nice if there was a "grandfather" clause. Spencer will clarify with other states the MME's they use.

Utilization of Stimulants and SUPPORT Act medications will be reviewed for the July 2021 meeting. The members were asked about the Powerpoint slides they received from Saunders. To clarify, the DUR Board members would like to see data reported out from the most recent full month. This will serve the Board better than a CY 2020 which ends in December 2020.

The question of how often to review the SUPPORT Act data was raised. Ross requested the percentage of patients using the medications. Spencer Moore will run that report for the July 2021 meeting. The members requested neighboring state information and Moore will run that scenario also for the July 2021 meeting. The members feel that a six month frequency is adequate for the review of SUPPORT Act data.

HAE Prior Authorization form review – Dianne Garside started the review of the PA form. The PDL link will be fixed so the current PDL will be brought up. The suggestion was made to add a date of update on the form and differentiate between acute and prophylaxis use medications. This will be followed up on. Motion by Houghton and second by Wergin to accept form with recommendations. Motion voted upon and passed.

Asthma Immunomodulator PA form – Garside reviewed the PA form. It was brought up that the form will be dated and updated as needed and the PDL link will be fixed so the link will take the user to the current PDL. Changes (including adding generic names) to the form will be made with Magellan's assistance and will be brought back for the July 2021 DUR Board meeting.

VII. Prospective DUR / New Project Requests

Glucagon use review was discussed. It was requested to analyze the patients on insulin or sulfonylureas and do not have orders for glucagon. Moore will research the request.

VIII. Future Meeting Dates

The next DUR Board meeting will be Tuesday July 13, 2021. Ken Saunders reminded everyone that the July meeting will probably be a virtual meeting and to watch the DUR Board website for the WEBEX meeting information, the Agenda and the DRAFT Minutes. The meeting will begin at 6:30 PM CDT.

IX. Concerns & Comments

There were no concerns or comments by any of the DUR Board members, DHHS Staff, MCO's, or Public members. Dianne Garside did want to remind everyone that the Hepatitis C treatment scoring will go from a F2 to F0.

X. Adjournment

A motion was made by Wergin to adjourn the meeting. A second was made by Charlie Moore. The vote was unanimously approved. The meeting was adjourned at 8:36 PM.